Trials / Completed
CompletedNCT01426919
Evaluation of Biomarkers of Traumatic Brain Injury
A Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,011 (actual)
- Sponsor
- Banyan Biomarkers, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other clinical information within 12 hours of injury to assist in determining the need for a CT scan of the head.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Head CT scan and blood draw within 12 hours of injury |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2011-09-01
- Last updated
- 2020-12-16
Locations
24 sites across 3 countries: United States, Germany, Hungary
Source: ClinicalTrials.gov record NCT01426919. Inclusion in this directory is not an endorsement.